Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Change in Account Payables (2018 - 2025)

Autolus Therapeutics (AUTL) has disclosed Change in Account Payables for 5 consecutive years, with $5.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables rose 1864.13% year-over-year to $5.4 million, compared with a TTM value of $9.1 million through Sep 2025, up 1243.17%, and an annual FY2024 reading of $1.6 million, up 412.38% over the prior year.
  • Change in Account Payables was $5.4 million for Q3 2025 at Autolus Therapeutics, up from $1.5 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $5.4 million in Q3 2025 and bottomed at -$3.2 million in Q3 2023.
  • Average Change in Account Payables over 4 years is $833833.3, with a median of $303500.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables crashed 630.28% in 2023, then soared 1864.13% in 2025.
  • Year by year, Change in Account Payables stood at $109000.0 in 2022, then plummeted by 630.28% to -$578000.0 in 2023, then soared by 157.27% to $331000.0 in 2024, then skyrocketed by 1537.76% to $5.4 million in 2025.
  • Business Quant data shows Change in Account Payables for AUTL at $5.4 million in Q3 2025, $1.5 million in Q2 2025, and $1.9 million in Q1 2025.